Hedge Funds Weigh In On Biocryst Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc Decreased by Analyst (NASDAQ:BCRX)

FY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc Decreased by Analyst (NASDAQ:BCRX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Rice hall james associatesBiocryst pharmaceuticals incNews ratings for biocryst pharmaceuticals dailyVanguard group incBiocryst pharmaceuticalsBiocryst pharmaceuticals stock performanceNeedham companyJump financialDeerfield management companylp seriesHedge funds weigh in on biocryst pharmaceuticalsFree reportBiocryst pharmaceuticalCryst pharmaceuticalsGet free reportRice hall jamesHall james

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives $13 29 Consensus Target Price from Analysts

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives $13 29 Consensus Target Price from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Biocryst pharmaceuticals company profileHedge funds weigh in on biocryst pharmaceuticalsVanguard group incBiocryst pharmaceuticalsBiocryst pharmaceuticals price performanceNews ratings for biocryst pharmaceuticals dailyCounterweight venturesNeedham companyBiocryst pharmaceuticals incPricet rowe associates incAnalyst recommendations for biocryst pharmaceuticalsGoldman sachs group incGet free reportMarketbeat ratingsCryst pharmaceuticalsSachs group

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Consensus Rating of Buy from Analysts

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Receives Consensus Rating of Buy from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

News ratings for biocryst pharmaceuticals dailyBiocryst pharmaceuticals incDeerfield management companylp seriesAnalyst recommendations for biocryst pharmaceuticalsRice hall james associatesBiocryst pharmaceuticals company profileBiocryst pharmaceuticals stock performanceHedge funds weigh in on biocryst pharmaceuticalsBiocryst pharmaceuticalsJump financialNeedham companyGet free reportCryst pharmaceuticalsCapital managementRice hall jamesHall james

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 30,130,000 shares, a decline of 31.8% from the October 15th total of 44,190,000 shares. Based on an average daily volume of 2,770,000 shares, […]

United statesBiocryst pharmaceuticals stock performanceNews ratings for biocryst pharmaceuticals dailyJpmorgan chase coRoyal bankBiocryst pharmaceuticals incMetlife investment managementAmerican century companies incJefferies financial groupBiocryst pharmaceuticals company profileNeedham companyYork mellon corpBiocryst pharmaceuticalsHedge funds weigh in on biocryst pharmaceuticalsFairfield bushGet free report

BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to Outperform at Royal Bank of Canada

Royal Bank of Canada upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a sector perform rating to an outperform rating in a research report sent to investors on Monday morning, Marketbeat.com reports. Royal Bank of Canada currently has $10.00 price target on the biotechnology company’s stock, up from their prior price target of […]

Nova scotiaUnited statesHedge funds weigh in on biocryst pharmaceuticalsNews ratings for biocryst pharmaceuticals dailyVanguard group incBiocryst pharmaceuticals incBiocryst pharmaceuticals trading downRoyal bankNeedham companyAvoro capital advisorsBiocryst pharmaceuticalsJefferies financial groupAnalyst recommendations for biocryst pharmaceuticalsBlackrock incFree reportFinancial group